Table 2 Incidence of cancer and stratified analysis with adjusted hazard ratios by multivariate Cox proportional hazards regression analysis for study cohort

AHA

 No

1130

206599

54.7

ref

ref

 Yes

187

17912

104

1.92(1.64–2.24)

1.78(1.50–2.12)

 Non-Autoimmune AHA

119

12107

98.3

1.81(1.50–2.19)

1.87(1.53–2.29)

 Autoimmune AHA

68

5805

117

2.15(1.68–2.75)

2.01(1.56–2.59)

Age group

  < 25

9

55421

1.62

ref

ref

 25–39

54

52892

10.2

6.32(3.12–12.8)

6.78(3.35–13.7)

  ≥ 40

1254

116197

108

66.9(34.7–129)

65.37(33.9–126)

Sex

 Female

606

127460

47.5

ref

ref

 Male

711

97051

73.3

1.54(1.38–1.71)

1.50(1.34–1.67)

Urbanization of residency

 1 (highest)

282

53113

53.1

ref

ref

 2

446

77556

57.5

1.08(0.93–1.25)

0.99(0.85–1.14)

 3

185

34097

54.3

1.02(0.85–1.23)

1.12(0.93–1.34)

 4+ (lowest)

404

59745

67.6

1.27(1.09–1.48)

1.08(0.93–1.26)

Comorbidity

 DM

 No

1128

210752

53.5

ref

ref

 Yes

189

13759

137

2.61(2.24–3.05)

1.29(1.10–1.51)

SLE

 No

1309

223337

58.6

ref

ref

 Yes

8

1174

68.2

1.18(0.59–2.37)

1.04(0.51–2.12)

Alcohol^a

 No

1297

223606

58.0

ref

ref

 Yes

20

905

221

3.88(2.49–6.04)

1.09(0.66–1.81)

Splenomegaly

 No

1303

223914

58.2

ref

ref

 Yes

14

597

235

4.10(2.42–6.94)

1.50(0.85–2.66)

CKD

 No

1284

223018

57.6

ref

ref

 Yes

33

1493

221

3.91(2.77–5.52)

1.54(1.08–2.21)

Liver cirrhosis

 No

1278

223469

57.2

ref

ref

 Yes

39

1042

374

6.71(4.88–9.24)

1.96(1.30–2.94)

RA

 No

1314

224077

58.6

ref

ref

 Yes

3

434

69.1

1.2(0.39–3.71)

0.79(0.25–2.47)

HBV

 No

1303

223738

58.2

ref

ref

 Yes

14

773

181

3.15(1.86–5.33)

1.38(0.80–2.38)

HCV

 No

1286

223814

57.5

ref

ref

 Yes

31

697

445

7.99(5.59–11.4)

2.78(1.89–4.08)